PT  - JOURNAL ARTICLE
AU  - Fortmann, Seth D.
AU  - Patton, Michael J.
AU  - Frey, Blake F.
AU  - Vieira, Cristiano P.
AU  - Reddy, Sivani B.
AU  - Huls, Forest
AU  - Crouse, Andrew
AU  - Floyd, Jason
AU  - Prasad, Ram
AU  - Hanumanthu, Vidya Sagar
AU  - Sterrett, Sarah
AU  - Zucker, Jeremy D.
AU  - Li, Peng
AU  - Erdmann, Nathan
AU  - Goepfert, Paul A.
AU  - Gaggar, Amit
AU  - Grant, Maria B.
AU  - Might, Matthew
TI  - Megakaryocytes are a Novel SARS-CoV-2 Infection Target and Risk Factor for Mortality and Multi-Organ Failure
AID  - 10.1101/2021.08.05.21261552
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.05.21261552
4099  - http://medrxiv.org/content/early/2021/08/07/2021.08.05.21261552.short
4100  - http://medrxiv.org/content/early/2021/08/07/2021.08.05.21261552.full
AB  - Discovery of a biomarker for patients at high risk of progression to severe Coronavirus Disease 2019 (COVID-19) is critical for clinical management, particularly in areas of the world where widespread vaccine distribution and herd immunity have yet to be achieved. Herein, we characterize peripheral blood from 218 COVID-19 patients with flow cytometry and provide evidence that megakaryocytes are a target for infection by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We demonstrate a positive correlation between infected megakaryocytes expressing the protein calprotectin (also called S100A8/A9), a known marker of COVID-19 severity. Additionally, we show that infected, calprotectin expressing megakaryocytes are correlated with COVID-19 severity and are a prognostic indicator of 30-day clinical outcomes including respiratory failure, thrombotic events, acute kidney injury (AKI), ICU admission, and mechanical ventilation. These findings represent a novel SARS-CoV-2 infection target with significant clinical implications as a biomarker for clinical outcomes associated with severe COVID-19.Competing Interest StatementMaria B. Grant, Matthew Might, Seth D. Fortmann, Michael J. Patton, and Amit Gagger are listed as co-inventors on a provisional patent for using circulating infected megakaryocytes as a prognostic biomarker in COVID-19.Funding StatementFunding for this research was contributed by Dr. Matthew Might with University of Alabama at Birmingham Precision Medicine Institute (PMI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all patients, and the study protocol was IRB approved (UAB; IRB-300006291).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon acceptance of the manuscript for publication, an UAB approved subset of de-identified data pertaining to the analyses within the manuscript will be made available.